Literature DB >> 3753607

Studies on the mechanism of membrane fusion: site-specific mutagenesis of the hemagglutinin of influenza virus.

M J Gething, R W Doms, D York, J White.   

Abstract

Oligonucleotide-directed mutagenesis of a cDNA encoding the hemagglutinin of influenza virus has been used to introduce single base changes into the sequence that codes for the conserved apolar "fusion peptide" at the amino-terminus of the HA2 subunit. The mutant sequences replaced the wild-type gene in SV40-HA recombinant virus vectors, and the altered HA proteins were expressed in simian cells. Three mutants have been constructed that introduce single, nonconservative amino acid changes in the fusion peptide, and three fusion phenotypes were observed: substitution of glutamic acid for the glycine residue at the amino-terminus of HA2 abolished all fusion activity; substitution of glutamic acid for the glycine residue at position 4 in HA2 raised the threshold pH and decreased the efficiency of fusion; and, finally, extension of the hydrophobic stretch by replacement of the glutamic acid at position 11 with glycine yielded a mutant protein that induced fusion of erythrocytes with cells with the same efficiency and pH profile as the wild-type protein. However, the ability of this mutant to induce polykaryon formation was greatly impaired. Nevertheless, all the mutant proteins underwent a pH-dependent conformational change and bound to liposomes. These results are discussed in terms of the mechanism of HA-induced membrane fusion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753607      PMCID: PMC2114034          DOI: 10.1083/jcb.102.1.11

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  48 in total

1.  Activation of influenza A viruses by trypsin treatment.

Authors:  H D Klenk; R Rott; M Orlich; J Blödorn
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

2.  THE AGGLUTINATION OF RED CELLS BY ALLANTOIC FLUID OF CHICK EMBRYOS INFECTED WITH INFLUENZA VIRUS.

Authors:  G K Hirst
Journal:  Science       Date:  1941-07-04       Impact factor: 47.728

3.  Sequence determination of the Sendai virus fusion protein gene.

Authors:  B M Blumberg; C Giorgi; K Rose; D Kolakofsky
Journal:  J Gen Virol       Date:  1985-02       Impact factor: 3.891

4.  Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors.

Authors:  M J Zoller; M Smith
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Proteolytic activation of the influenza virus hemagglutinin: The structure of the cleavage site and the enzymes involved in cleavage.

Authors:  W Garten; F X Bosch; D Linder; R Rott; H D Klenk
Journal:  Virology       Date:  1981-12       Impact factor: 3.616

6.  Cloning and DNA sequence of double-stranded copies of haemagglutinin genes from H2 and H3 strains elucidates antigenic shift and drift in human influenza virus.

Authors:  M J Gething; J Bye; J Skehel; M Waterfield
Journal:  Nature       Date:  1980-09-25       Impact factor: 49.962

7.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

8.  Studies on transformation of Escherichia coli with plasmids.

Authors:  D Hanahan
Journal:  J Mol Biol       Date:  1983-06-05       Impact factor: 5.469

9.  Nucleotide sequence of the rightward operator of phage lambda.

Authors:  T Maniatis; A Jeffrey; D G Kleid
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

10.  Mutations in the cytoplasmic domain of the influenza virus hemagglutinin affect different stages of intracellular transport.

Authors:  C Doyle; M G Roth; J Sambrook; M J Gething
Journal:  J Cell Biol       Date:  1985-03       Impact factor: 10.539

View more
  121 in total

1.  Implicit solvent model studies of the interactions of the influenza hemagglutinin fusion peptide with lipid bilayers.

Authors:  D Bechor; N Ben-Tal
Journal:  Biophys J       Date:  2001-02       Impact factor: 4.033

2.  Mutational evidence for an internal fusion peptide in flavivirus envelope protein E.

Authors:  S L Allison; J Schalich; K Stiasny; C W Mandl; F X Heinz
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  A specific point mutant at position 1 of the influenza hemagglutinin fusion peptide displays a hemifusion phenotype.

Authors:  H Qiao; R T Armstrong; G B Melikyan; F S Cohen; J M White
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

4.  A theoretical investigation into the lipid interactions of m-calpain.

Authors:  A Daman; F Harris; S Biswas; J Wallace; D A Phoenix
Journal:  Mol Cell Biochem       Date:  2001-07       Impact factor: 3.396

5.  Stochastic simulation of hemagglutinin-mediated fusion pore formation.

Authors:  S Schreiber; K Ludwig; A Herrmann; H G Holzhütter
Journal:  Biophys J       Date:  2001-09       Impact factor: 4.033

6.  Investigation of pathways for the low-pH conformational transition in influenza hemagglutinin.

Authors:  M Madhusoodanan; Themis Lazaridis
Journal:  Biophys J       Date:  2003-03       Impact factor: 4.033

7.  The complete influenza hemagglutinin fusion domain adopts a tight helical hairpin arrangement at the lipid:water interface.

Authors:  Justin L Lorieau; John M Louis; Ad Bax
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

8.  Membrane fusion mediated by coiled coils: a hypothesis.

Authors:  J Bentz
Journal:  Biophys J       Date:  2000-02       Impact factor: 4.033

9.  Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus.

Authors:  P J Gallagher; J M Henneberry; J F Sambrook; M J Gething
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Studies of the membrane fusion activities of fusion peptide mutants of influenza virus hemagglutinin.

Authors:  D A Steinhauer; S A Wharton; J J Skehel; D C Wiley
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.